Medscape | Antineutrophil Cytoplasm Antibody-Associated Vasculitis Medscape Rituximab, an anti-CD20 monoclonal antibody, has proven efficacy in remission induction therapy for AAV, and two trials with rituximab as remission maintenance therapy are ongoing. Clinical trials evaluating mycophenolate mofetil as remission induction ... |
